+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Guillain Barre Syndrome Drug"

From
Guillain-Barre Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Guillain-Barre Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Guillain-Barre Syndrome (GBS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Guillain-Barre Syndrome (GBS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Guillain-Barre Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Guillain-Barre Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 84 Pages
  • Global
From
  • 15 Results (Page 1 of 1)
Loading Indicator

The Guillain Barre Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat Guillain Barre Syndrome, a rare autoimmune disorder that affects the peripheral nervous system. The drugs used to treat this disorder are typically immunomodulatory agents, such as intravenous immunoglobulin, plasma exchange, and corticosteroids. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to recover from the disorder. The Guillain Barre Syndrome Drug market is highly competitive, with many companies offering treatments for the disorder. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies, such as Biogen, AbbVie, and Johnson & Johnson, also offer treatments for the disorder. Show Less Read more